These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24461717)

  • 1. Evaluation of full costs of care for patients with Alzheimer's disease in France: the predominant role of informal care.
    Gervès C; Chauvin P; Bellanger MM
    Health Policy; 2014 May; 116(1):114-22. PubMed ID: 24461717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Analysis of Formal Care, Informal Care, and Productivity Losses in Primary Care Patients who Screened Positive for Dementia in Germany.
    Michalowsky B; Thyrian JR; Eichler T; Hertel J; Wucherer D; Flessa S; Hoffmann W
    J Alzheimers Dis; 2016; 50(1):47-59. PubMed ID: 26639964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Analysis of the Public Financial Support Eligibility Rule for French Dependent Elders with Alzheimer's Disease.
    Rapp T; Lacey L; Ousset PJ; Cowppli-Bony P; Vellas B; Orgogozo JM
    Value Health; 2015 Jul; 18(5):553-9. PubMed ID: 26297082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of costs of care for patients with Alzheimer's disease.
    Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
    Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis of early psychosocial intervention in Alzheimer's disease.
    Søgaard R; Sørensen J; Waldorff FB; Eckermann A; Buss DV; Waldemar G
    Dement Geriatr Cogn Disord; 2014; 37(3-4):141-53. PubMed ID: 24157706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
    Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
    Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.
    Behrens S; Rattinger GB; Schwartz S; Matyi J; Sanders C; DeBerard MS; Lyketsos CG; Tschanz JT
    Int Psychogeriatr; 2018 Oct; 30(10):1499-1507. PubMed ID: 29559029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
    Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
    Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences of Anosognosia on the Cost of Caregivers' Care in Alzheimer's Disease.
    Turró-Garriga O; Garre-Olmo J; Reñé-Ramírez R; Calvó-Perxas L; Gascón-Bayarri J; Conde-Sala JL
    J Alzheimers Dis; 2016 Oct; 54(4):1551-1560. PubMed ID: 27636844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain.
    Lopez-Bastida J; Serrano-Aguilar P; Perestelo-Perez L; Oliva-Moreno J
    Neurology; 2006 Dec; 67(12):2186-91. PubMed ID: 17190942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between severity of Alzheimer's disease and costs of caring.
    Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
    CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economics of the Iceberg: Informal Care Provided to French Elderly with Dementia.
    Paraponaris A; Davin B
    Value Health; 2015 Jun; 18(4):368-75. PubMed ID: 26091590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.
    Reese JP; Hessmann P; Seeberg G; Henkel D; Hirzmann P; Rieke J; Baum E; Dannhoff F; Müller MJ; Jessen F; Geldsetzer MB; Dodel R
    J Alzheimers Dis; 2011; 27(4):723-36. PubMed ID: 21876256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of dementia from the societal perspective: is care provided in the community really cheaper than nursing home care?
    König HH; Leicht H; Brettschneider C; Bachmann C; Bickel H; Fuchs A; Jessen F; Köhler M; Luppa M; Mösch E; Pentzek M; Werle J; Weyerer S; Wiese B; Scherer M; Maier W; Riedel-Heller SG;
    J Am Med Dir Assoc; 2014 Feb; 15(2):117-26. PubMed ID: 24321877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost of Alzheimer's disease in managed care: a cross-sectional study.
    Leon J; Neumann PJ
    Am J Manag Care; 1999 Jul; 5(7):867-77. PubMed ID: 10557408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
    Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
    Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making Implicit Assumptions Explicit in the Costing of Informal Care: The Case of Head and Neck Cancer in Ireland.
    Hanly P; Maguire R; Balfe M; O'Sullivan E; Sharp L
    Pharmacoeconomics; 2017 May; 35(5):591-601. PubMed ID: 28205149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.